Suzuken CoTSE:9987 +0.12%74 ROE % is 6.95% as of Mar. 2026, which is 13% above its 10-year median of 6.17. GuruFocus rates TSE:9987 with a GF Score™ of 74/100 and a GF Value™ of 円5,907.58 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 115 Medical Distribution companies, Suzuken Co ranks better than 65.22% on this metric.
ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Suzuken Co's annualized net income for the quarter that ended in Mar. 2026 was 円28,516 Mil. Suzuken Co's average Total Stockholders Equity over the quarter that ended in Mar. 2026 was 円410,475 Mil. Therefore, Suzuken Co's annualized ROE % for the quarter that ended in Mar. 2026 was 6.95%.
The historical rank and industry rank for Suzuken Co's ROE % or its related term are showing as below:
TSE:9987'
s ROE % Range Over the Past 10 Years
Min: 1.9 Med: 6.17 Max: 9.37
Current: 9.37
During the past 13 years, Suzuken Co's highest ROE % was 9.37%. The lowest was 1.90%. And the median was 6.17%.
TSE:9987's ROE % is ranked better than 65.22% of 115
companies
in the Medical Distribution industry
Industry Median: 7.1
vs TSE:9987: 9.37
Suzuken Co (TSE:9987) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Suzuken Co ROE % Related Terms
Suzuken Co ROE % Historical Data
* Premium members only.
The historical data trend for Suzuken Co's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Suzuken Co's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Suzuken Co ROE % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Suzuken Co's ROE % distribution charts can be found below:
* The bar in red indicates where Suzuken Co's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Suzuken Co (TSE:9987) has a ROE % of 6.95% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Suzuken Co and its competitors. This is 13% above median its historical median of 6.17. Over the past decade, Suzuken Co's ROE % has ranged from 1.90 to 9.37. According to the industry distribution chart, Suzuken Co ranks #40 out of 115 companies in the Medical Distribution industry, placing it in the top 34.8%.
Is Suzuken Co's ROE % too high?
Suzuken Co's current ROE % of 6.95% is 13% above median its 10-year median of 6.17. Over the past 10 years, this metric has ranged from a low of 1.90 to a high of 9.37. The Medical Distribution industry median ROE % is 7.10. Suzuken Co's value of 6.95% is 2.1% below this industry median. Based on the distribution chart, Suzuken Co ranks #40 out of 115 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Suzuken Co has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Suzuken Co's ROE % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Suzuken Co ranks #40 out of 115 companies for ROE %. This puts Suzuken Co in the upper half of its industry. The industry median ROE % is 7.10. Suzuken Co's value of 6.95% is 2.1% below this benchmark. Historically, Suzuken Co's own ROE % has ranged from 1.90 to 9.37 over the past decade. While the company's 10-year median is 6.17 vs. the industry median of 7.10, Suzuken Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Distribution company?
The median ROE % among Medical Distribution companies is 7.10, based on 115 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Suzuken Co's current ROE % of 6.95% is 2.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Suzuken Co and its competitors. For the Medical Distribution industry, the median ROE % is 7.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Suzuken Co's current ROE % is 6.95%, which is 13% above median its own 10-year median of 6.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Suzuken Co stock overvalued right now?
Based on GuruFocus' analysis, Suzuken Co (TSE:9987) is currently considered Modestly Undervalued. The stock's GF Value™ is 円5,907.58, compared to a current price of 円4,976.00 — trading 15.8% below its estimated fair value. The current ROE % is 6.95%, which is 13% above median its 10-year median of 6.17 and 2.1% below the Medical Distribution industry median of 7.10. Suzuken Co's overall GF Score™ is 74/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Suzuken Co (TSE:9987), the current ROE % is 6.95% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Suzuken Co (TSE:9987) Overvalued in 2026?
Based on GuruFocus' analysis, Suzuken Co stock appears to be undervalued.
The current stock price of 円4,976.00 is trading 15.8% below its estimated GF Value™ of 円5,907.58.
GuruFocus considers Suzuken Co to be Modestly Undervalued.
Key valuation signals for TSE:9987:
ROE %: 6.95% (13% above median its 10-year median of 6.17)
GF Value™: 円5,907.58 vs. price of 円4,976.00 (15.8% below fair value)
Industry Position: 2.1% below the Medical Distribution median (#40 of 115)
No single metric tells the full story. See the TSE:9987 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Suzuken Co Ltd is engaged in the manufacture and sale of pharmaceuticals and medical devices, and in providing insurance, pharmacy, and nursing care services. The company operates through segments, including Pharmaceutical Wholesale business, Healthcare product development business, Specialty Pharmaceuticals Distribution business, Regional medical nursing care support business, and Medical-related Services business. It generates the majority of its revenue from the Pharmaceutical Wholesale Business segment, which sells prescription pharmaceuticals, diagnostic reagents, medical equipment, and medical supplies.
74GF Score
Get the complete analysis for TSE:9987
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:9987 has been successfully added to your 
